Loading clinical trials...

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia

NCT00300963•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects must have schizophrenia which is not secondary to another medical condition or substance abuse.
•Require inpatient hospitalization.
•Women may enroll only if they are not of child-bearing potential OR are on a protocol-approved birth control method.

Exclusion Criteria

•Subject is in their first episode of schizophrenia.
•Subject has other psychotic disorders or bipolar disorder.
•Subject has schizophrenia symptoms from taking another medicine or drug of abuse, or due to a general medical condition.
•Subject has a recent history of substance dependence, or tests positive for illicit drug.
•Subject has an unstable medical disorder, or any significant medical disorder including autistic disorder, organic brain disease, liver dysfunction, epilepsy or seizures, or is at increased risk of developing cerebrovascular problems like stroke.
•Subject has any significant abnormalities in any of the screening tests (ECGs, labs, physical examinations, etc.).
•Subject poses a current serious suicidal or homicidal risk.
•Subject has a positive pregnancy test, or is lactating or planning to become pregnant within one month of the study.
•Subject has recently or is currently participating in another clinical study.
•Subject is stabilized on their current schizophrenia treatment.
+3 more criteria

Locations (20)

GSK Investigational Site

Little Rock, Arkansas, United States

GSK Investigational Site

Anaheim, California, United States

GSK Investigational Site

Cerritos, California, United States

GSK Investigational Site

Garden Grove, California, United States

GSK Investigational Site

Glendale, California, United States

GSK Investigational Site

National City, California, United States

GSK Investigational Site

Oceanside, California, United States

GSK Investigational Site

Pico Rivera, California, United States

GSK Investigational Site

Rosemead, California, United States

GSK Investigational Site

San Diego, California, United States

Key Dates

Start Date

December 1, 2004

Primary Completion Date

October 1, 2005

Completion Date

October 1, 2005

Last Updated

February 15, 2013

Enrollment

275

Estimated participants

Conditions

Schizophrenia

Interventions

Talnetant

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 15, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Brain Stimulation to the Hippocampus in Schizophrenia

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques